The Boston-based firm is pursuing nanopore technology as a readout for its unique information-encoding format, which could help customers store vast amounts of data.
The nanopore sequencing-based test is designed to both diagnose SARS-CoV-2 infection, as well as monitor mutations that may affect efforts to combat the virus.
The survey further characterized antibiotic resistance genes within these communities, suggesting that such an approach could aid in infection control efforts.
The first version of the platform, which the company submitted for Emergency Use Authorization to the US FDA last week, analyzes RNA extracted from a swab.
Combining Ubiquitome's handheld PCR device and Oxford Nanopore's sequencer may enable a single person to screen 500 samples and obtain 24 whole genome sequences per day.
